Table 3.
Multivariable predictors of biochemical recurrence in the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort
| Variable | HR | 95%CI | P |
|---|---|---|---|
| PSA nadir (per 0.01 ng/mL) | 1.14 | 1.10–1.18 | <0.001 |
| Age (years) | 1.01 | 0.99–1.04 | 0.382 |
| Race | |||
| White | ref | – | – |
| Non-white | 1.37 | 1.02–1.97 | 0.035 |
| Body mass index (log[kg/m2]) | 3.02 | 1.15–7.92 | 0.025 |
| Year of surgery (years) | 0.96 | 0.89–1.03 | 0.221 |
| Preoperative PSA (log[ng/mL]) | 1.25 | 0.99–1.59 | 0.066 |
| Clinical T stage | |||
| T1 | ref | – | – |
| T2–T3 | 1.17 | 0.85–1.61 | 0.333 |
| Pathological Gleason score | |||
| 2–6 | ref | – | – |
| 3 + 4 | 2.04 | 1.33–3.15 | 0.001 |
| ≥4 + 3 | 2.75 | 1.71–4.43 | <0.001 |
| Surgical findings | |||
| OC and M- | ref | – | – |
| PSM or ECE | 1.99 | 1.39–2.84 | <0.001 |
| SVI | 2.68 | 1.44–4.97 | 0.002 |
| Prostate weight (log[g]) | 0.72 | 0.47–1.11 | 0.137 |
CI, confidence interval; ECE, extracapsular extension; HR, hazard ratio; OC and M-, organ-confined and margin-negative; PSA, prostate-specific antigen; PSM, positive surgical margins; SVI, seminal vesicle invasion.